Lung Cancer Clinical Trials in Miami

Showing 401-404 of 404 trials

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

NCT00088088

This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are randomly assigned to receive either paclitaxel and carboplatin or paclitaxel and carboplatin and study drug (STA 4783). Treatment will be every 3 weeks for 6 cycles.

Stage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer

Synta Pharmaceuticals Corp.86 participantsStarted Mar 2004

Jonesboro, Arkansas, United States • Pomona, California, United States • San Francisco, California, United States +16 more locations

COMPLETEDPhase 2< 1 mile

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

NCT00051974

The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you and your cancer.

Non-Small Cell Lung Cancer

Millennium Pharmaceuticals, Inc.155 participantsStarted Dec 2002

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +17 more locations

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer Trials in Other Cities

Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer

Subcutaneous Amifostine Safety Study

Other Conditions in Miami